The Effect of Duloxetine on Painful Physical Symptoms in Depressed Patients: Do Improvements in These Symptoms Result in Higher Remission Rates?
The DOI matches its Crossref record.
Abstract
BACKGROUND: Depression is a chronic disease consisting of emotional/psychological and physical symptoms. Emotional symptoms have been shown to respond to currently available antidepressants; however, physical symptoms may not be as responsive. It was hypothesized that resolution of both psychological and physical symptoms of depression would predict a higher percentage of patients achieving remission. METHOD: Efficacy data were pooled from 2 identical, but independent, 9-week randomized, double-blind clinical trials of duloxetine 60 mg q.d. (N = 251) and placebo (N = 261). All patients met diagnostic criteria for DSM-IV major depressive disorder, which was confirmed by the Mini-International Neuropsychiatric Interview. Efficacy measures included the 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score, the HAM-D-17 Maier subscale, the Clinical Global Impressions-Severity of Illness (CGI-S) scale, the Patient Global Impression of Improvement (PGI-I) scale, the Somatic Symptom Inventory, the Quality of Life in Depression Scale, and Visual Analog Scales (VAS) for pain (overall pain, headaches, back pain, shoulder pain, interference with daily activities, and time in pain while awake). RESULTS: Duloxetine-treated patients demonstrated significantly greater improvement in overall pain (p =.016), back pain (p =.002), and shoulder pain (p =.021) at week 9 compared with patients receiving placebo. When treatment effects were pooled over all visits, patients receiving duloxetine, 60 mg q.d., exhibited significantly greater improvement than placebo-treated patients in 5 of the 6 assessed VAS pain measures. Approximately 50% of the improvement in overall pain was independent of improvement in HAM-D-17 total score. Assuming the same level of improvement in core emotional symptoms of depression (Maier subscale), improvement in overall pain severity was associated with higher estimated probabilities of remission (p <.001). The week 9 means for VAS overall pain severity were 13.0 for remitters (last observed value for HAM-D-17 was < or = 7) compared with 22.7 for nonremitters (p <.001), respectively, representing a greater than 3-fold improvement from baseline in remitters. The remission rate for pain responders (improvement in VAS overall pain from baseline to last observation > or = 50%) was twice that observed for pain nonresponders (36.2% vs. 17.8%, p <.001). Greater improvements in pain outcomes were associated with more favorable endpoint outcomes on the CGI-S and PGI-I scales. In addition, early favorable responses in VAS overall pain severity were associated with favorable endpoint outcomes. CONCLUSIONS: Treatment with duloxetine, 60 mg q.d., significantly reduced pain compared with placebo. Improvements in pain severity were attributable equally to the direct effect of duloxetine and to associated changes in depression severity. Improvement in painful physical symptoms was associated with higher remission rates even after accounting for improvement in core emotional symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Self-citationDemyttenaere, K., Bruffaerts, R., Lee, S., Posada-Villa, J., Kovess, V., Angermeyer, M. C., Levinson, D., de Girolamo, G., Nakane, H., Mneimneh, Z., et al. (2007) · Pain · doi:10.1016/j.pain.2007.01.022 · Cited by 608
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007115.pub3 · Cited by 565
Neurobiology of depression: an integrated view of key findings
Maletic, V., Robinson, M., Oakes, T., Iyengar, S., Ball, S. G., & Russell, J. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01602.x · Cited by 382
Somatic symptoms in depression
Kapfhammer, H.-P. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/hpkapfhammer · Cited by 320
Sultan, A., Gaskell, H., Derry, S., & Moore, R. A. (2008) · BMC Neurology · doi:10.1186/1471-2377-8-29 · Cited by 291
Schmidt, N. B., Eggleston, A. M., Woolaway-Bickel, K., Fitzpatrick, K. K., Vasey, M. W., & Richey, J. A. (2007) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2006.06.002 · Cited by 261
Defining and Measuring Functional Recovery from Depression
Greer, T. L., Kurian, B. T., & Trivedi, M. H. (2010) · CNS Drugs · doi:10.2165/11530230-000000000-00000 · Cited by 222
Comorbid painful physical symptoms and depression: prevalence, work loss, and help seeking
Demyttenaere, K., Bonnewyn, A., Bruffaerts, R., Brugha, T., De Graaf, R., & Alonso, J. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.01.007 · Cited by 217
Antidepressant Agents for the Treatment of Chronic Pain and Depression
Jann, M. W., & Slade, J. H. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.11.1571 · Cited by 172
Approach to the Patient with Multiple Somatic Symptoms
Croicu, C., Chwastiak, L., & Katon, W. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.06.007 · Cited by 81
“It is important to optimize the management of pain that commonly cooccurs with depression, because this can improve treatment outcomes and quality of life.(72) Some studies have shown that although the burden of physical symptoms diminishes significantly in the first month of selective serotonin reuptake inhibitor (SS…”
BackgroundStrategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms
Kurian, B. T., Greer, T. L., & Trivedi, M. H. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.53 · Cited by 73
Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113480990 · Cited by 69
Perahia, D. G. S., Quail, D., Desaiah, D., Montejo, A. L., & Schatzberg, A. F. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.07.001 · Cited by 64
Lin, C.-H., Yen, Y.-C., Chen, M.-C., & Chen, C.-C. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.03.039 · Cited by 57
Metadata
- Authors
- Fava, M., Mallinckrodt, C. H., Detke, M. J., Watkin, J. G., & Wohlreich, M. M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-04-15
- Volume
- 65
- Issue
- 4
- Pages
- 521-530
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2001706056
- Cited by
- 212
- References
- 0
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.